Short answer
aTYR PHARMA INC (ATYR) filed an 8-K current report with the SEC on June 8, 2026 reporting Item 3.01 (Notice of Delisting). Nasdaq granted a second 180-day cure period, extending the $1 minimum bid-price deadline to November 30, 2026.
- This filing includes Item 3.01, an item that often signal trouble.
aTYR PHARMA INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.01 · Notice of Delisting
- Nasdaq granted a second 180-day cure period, extending the $1 minimum bid-price deadline to November 30, 2026
- Stock remains listed on Nasdaq Capital Market with no immediate delisting impact
- Compliance requires a closing bid price of at least $1 for 10 consecutive business days
- Company may pursue a reverse stock split if needed to restore compliance
- Failure to comply could trigger delisting, subject to a potentially unsuccessful appeal process
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other aTYR PHARMA INC 8-K filings
Get the next ATYR 8-K as it lands
Follow ATYR for push alerts, or ask the research agent what this filing means.